260 related articles for article (PubMed ID: 25349176)
21. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813
[TBL] [Abstract][Full Text] [Related]
22. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders.
Maurus K; Appenzeller S; Roth S; Brändlein S; Kneitz H; Goebeler M; Rosenwald A; Geissinger E; Wobser M
J Invest Dermatol; 2020 Oct; 140(10):2023-2031.e1. PubMed ID: 32147503
[TBL] [Abstract][Full Text] [Related]
24. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
Sigel JE; Hsi ED
Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
[TBL] [Abstract][Full Text] [Related]
26. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders.
Franchina M; Kadin ME; Abraham LJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1322-5. PubMed ID: 15894695
[TBL] [Abstract][Full Text] [Related]
27. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
28. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma.
Tomaszewski MM; Lupton GP; Krishnan J; May DL
J Cutan Pathol; 1995 Aug; 22(4):310-8. PubMed ID: 7499570
[TBL] [Abstract][Full Text] [Related]
29. [Primary cutaneous CD30+ lymphoproliferative disorders].
Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
[TBL] [Abstract][Full Text] [Related]
30. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity.
Rajashekara Swamy M; Pollock S; J Goldberg L; Shen L
J Cutan Pathol; 2021 May; 48(5):694-700. PubMed ID: 33533041
[TBL] [Abstract][Full Text] [Related]
31. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils.
Cepeda LT; Pieretti M; Chapman SF; Horenstein MG
Am J Surg Pathol; 2003 Jul; 27(7):912-8. PubMed ID: 12826883
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
33. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
34. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669
[TBL] [Abstract][Full Text] [Related]
35. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of NPM1-TYK2 fusion oncogene.
Kuravi S; Baker RW; Mushtaq MU; Saadi I; Lin TL; Vivian CJ; Valluripalli A; Abhyankar S; Ganguly S; Cui W; Elenitoba-Johnson KSJ; Welch DR; Jensen RA; Saunthararajah Y; McGuirk JP; Balusu R
NPJ Precis Oncol; 2022 Jan; 6(1):3. PubMed ID: 35042970
[TBL] [Abstract][Full Text] [Related]
37. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.
Moy A; Sun J; Ma S; Seminario-Vidal L
Dermatol Clin; 2019 Oct; 37(4):471-482. PubMed ID: 31466587
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
39. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
40. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
